BLOOMFIELD, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Andrew Aromando, Senior Vice President, Commercial Development and Operations, is scheduled to present at the C.E. Unterberg Towbin Emerging Growth Life Sciences Conference at The Palace Hotel in New York at 9:20 AM EDT on Wednesday, October 26.
The presentation will be webcast live via the Alfacell company website at www.alfacell.com, and will be available for replay.
Alfacell is one of approximately 90 invited Biotechnology, Medical Devices and Diagnostics, and Specialty Pharmaceuticals companies scheduled to present. For more information about the conference, visit www.unterberg.com.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE(R) (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Group Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.comacel@efcg.net
Alfacell CorporationCONTACT: Kuslima Shogen or Robert Love, both of Alfacell Corporation,+1-973-748-8082, info@alfacell.com; or Dodi Handy of Elite FinancialCommunications Group, +1-407-585-1080, acel@efcg.net, for AlfacellCorporation
